BioMedNewsBreaks – Silo Pharma Inc. (SILO) Produces First Batch of SPU-21 Liposomes for RA Study

Company: Silo Pharma Inc. (SILO)
Category: News

Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. The company today announced that it has produced its first batch of liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). According to the update, the ability of the SPU-21 to target inflamed epithelium suggest their potential use to target drug delivery. Silo’s novel joint homing peptides can be used to treat autoimmune diseases, which include but are not limited to rheumatoid arthritis (“RA”). This approach could enhance the therapeutic effect of current and future therapies and decrease potential toxicity. SPU-21 has potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. “The production and delivery of liposomes for our upcoming study with Frontage advances SPU-21 and allows us to further study anti-arthritic activity in animals,” Eric Weisblum, CEO of Silo Pharma, said in the press release. “We look forward to sharing the results of the study upon completion and data collection.”

To view the full press release, visit https://ibn.fm/49yQR

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050